.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J06A_ImmuneSera.J06AA04_BotulinumAntitoxin.BotulinumAntitoxin .Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J06A_ImmuneSera.J06AA04_BotulinumAntitoxin.BotulinumAntitoxin| name: | BotulinumAntitoxin | |
| ATC code: | J06AA04 | |
| route: | intravenous | |
| compartments: | 2 | |
| dosage: | 1 | mg |
| volume of distribution: | 3.5 | L |
| clearance: | 0.14 | L/h |
| other parameters in model implementation | ||
Botulinum antitoxin is an equine-derived immunoglobulin preparation used for the treatment of botulism, a rare but serious illness caused by botulinum toxin. It acts by binding to circulating toxin molecules, neutralizing their effect and limiting disease progression. The drug is used primarily in post-exposure therapy for botulism and is approved for this purpose by relevant health authorities.
No published pharmacokinetic data is available for botulinum antitoxin preparations (heptavalent, equine-derived) in humans. Pharmacokinetic values below are not based on primary literature but reflect expected values for large immunoglobulin proteins administered intravenously in adults.